Doctors Revision

Palliative Care

Palliative Pain Management

Management of pain, a common and distressing symptom in patients with life-limiting illness. Addresses assessment and treatment of nociceptive and neuropathic pain using a holistic approach and the WHO analgesic ladder.

Also known as: Pain Relief in Palliative Care

View images for Palliative Pain Management (Google Images, opens in a new tab)
On this page

Referral and warning signs

When to refer

Pain unresponsive to standard measures. Need for specialist palliative care input. Need for interventions like radiotherapy for bone pain or nerve blocks. Suspected cause requiring surgical intervention.

Red flags

  • Sudden worsening of pain.
  • New neurological symptoms associated with pain (e.g., weakness, numbness, incontinence - suggesting cord compression).
  • Signs of opioid toxicity (severe respiratory depression, pinpoint pupils, coma).
  • Pain associated with signs of acute abdomen or other surgical emergency.

Signs and symptoms

  • Patient report of pain (location, nature, severity).
  • Nociceptive Pain Features: Aching, throbbing (somatic); Colicky, pressure, cramping (visceral).
  • Neuropathic Pain Features: Burning, prickling, stinging, pins and needles, crawling sensation, numbness, hypersensitivity, shooting, electric shock.
  • Factors Increasing Pain Perception: Anxiety, depression, social abandonment, insomnia, lack of understanding.
  • Factors Decreasing Pain Perception: Relaxation, sleep, relief of other symptoms, understanding, venting feelings.

Risk factors

  • Underlying life-limiting illness (cancer, AIDS, organ failure, etc.).
  • Treatment side effects (chemotherapy, radiotherapy, surgery, ART).
  • Co-morbidities (arthritis, sickle cell crisis).
  • Psychosocial factors (anxiety, depression).

Diagnosis

Clinical assessment

Thorough pain assessment is key: Duration, Severity (0-5 scale), Site/Radiation, Nature (stabbing, throbbing etc.), Periodicity (constant/intermittent), Relieving/Aggravating factors, Accompanying symptoms. Assess for multiple pain types/sites. Targeted physical examination. Differentiate between Nociceptive (intact pathways, responds well to ladder) and Neuropathic pain (nerve damage, partial response to ladder, needs adjuvants).

Investigations

  • Investigations primarily target the underlying cause of pain (e.g., X-ray for bone mets/fracture, imaging for nerve compression).
  • No specific lab test for pain itself.

Diagnostic criteria

Based on patient report and clinical assessment characterizing the pain type (nociceptive vs. neuropathic) and severity to guide management according to the WHO analgesic ladder.

Management

Non-pharmacological management

  • Lifestyle adjustment.
  • Patient counselling and explanation.
  • Massage with aromatherapy oils (may help neuropathic/muscular pain).
  • Reflexology.
  • Application of heat or cold packs.
  • Relaxation techniques.
  • Distraction therapy.
  • Treat underlying cause where possible (e.g., surgery, radiotherapy for cancer).
  • Social and spiritual support.
  • Rest (e.g., for acute back pain on a firm surface).

Pharmacological treatment

  • WHO Analgesic Ladder Approach:
  • Step 1: Mild Pain (Non-opioid +/- Adjuvant)
  • - Paracetamol: 1g Q6H (Adult); 10-15mg/kg Q6H (Child). (Use 500mg in elderly). Caution liver toxicity with prolonged high doses.
  • - +/- NSAID: Ibuprofen 400mg Q6-8H (Adult); 5-10mg/kg Q6-8H (Child >3mo). OR Diclofenac 50mg Q8H (Adult).
  • - NSAIDs preferred for bone pain. Caution >10 days, renal impairment, GI risk.
  • Step 2: Moderate Pain (Weak Opioid/Low-Dose Morphine +/- Non-opioid +/- Adjuvant)
  • - Continue Step 1 analgesics.
  • - Low-Dose Morphine (Recommended 1st line if available): 2.5-5mg PO Q4H (Adult); Child doses see UCG table (start 0.01-0.2mg/kg based on age).
  • - OR Codeine 30-60mg Q6H (Adult max 240mg/day). Not used in children.
  • - OR Tramadol 50-100mg Q6H (Adult max 400mg/day). Not used in children.
  • - Add laxative (e.g., Bisacodyl 10-15mg nocte +/- Liquid Paraffin 10ml OD) unless diarrhoea present.
  • Step 3: Severe Pain (Strong Opioid +/- Non-opioid +/- Adjuvant)
  • - Continue Step 1 analgesics. STOP Step 2 weak opioids.
  • - Morphine: Start 7.5-10mg PO Q4H (Adult); Child doses see UCG table (adjust based on age). Double dose at night.
  • - Titrate dose up by 30-50% as needed for pain control.
  • - Breakthrough dose: Give equivalent additional dose as needed (e.g., before painful procedures). If used regularly, increase regular dose.
  • - Dose adjustment needed for elderly, renal impairment.
  • - Continue regular laxatives.
  • Adjuvants (Add at any step as appropriate):
  • - Neuropathic Pain:
  • - Amitriptyline 12.5-25mg nocte (Adult, max 50-75mg); 0.2-0.5mg/kg nocte (Child 2-12yrs, max 25mg). Avoid in heart disease.
  • - Carbamazepine (Stabbing pain/2nd line): Start 100mg BID (Adult); 5-20mg/kg/day divided (Child). Increase gradually.
  • - Clonazepam 0.5-1mg nocte (Adult, 2nd line).
  • - Phenytoin (for stabbing pain like trigeminal neuralgia - mentioned in 13.1.3 text)
  • - Bone Pain/Swelling/Nerve Compression:
  • - Dexamethasone 4-8mg OD (Adult).
  • - Prednisolone 1-2mg/kg/day (Child).
  • - Smooth Muscle Spasm:
  • - Hyoscine Butylbromide 20mg Q6H (Adult); Child doses see UCG table.
  • - Skeletal Muscle Spasm:
  • - Diazepam 5-20mg nocte (Adult); Child doses see UCG table.
  • General Opioid Principles:
  • - Give by the clock, by mouth, by the patient.
  • - Liquid morphine available and well-absorbed.
  • - Manage side effects proactively (see below).
  • - Cautions: Respiratory depression (rare with oral titration), head injury, severe liver/renal disease (adjust dose), elderly (adjust dose), concurrent CNS depressants.
  • - Avoid Pethidine for chronic pain.
  • Opioid Side Effect Management:
  • - Constipation: Bisacodyl +/- Liquid Paraffin (Prophylactic).
  • - Nausea/Vomiting (Usually transient): Metoclopramide 10mg Q8H PRN for 3-5 days (adjust dose for children).
  • - Drowsiness/Confusion: Titrate opioid dose down slowly if excessive and persistent.
  • - Respiratory Depression (Mainly parenteral use): Naloxone 0.4-2mg slow IV PRN (Adult); 0.01mg/kg slow IV (Child).

Monitoring

Regular pain assessment (score, relief). Monitor for and manage opioid side effects (constipation, nausea, drowsiness). Monitor effectiveness of adjuvants. Adjust doses based on response and side effects.

Complications

  • Uncontrolled pain leading to suffering and poor quality of life.
  • Opioid side effects (constipation, nausea, sedation, respiratory depression).
  • NSAID side effects (gastritis, renal toxicity, bleeding).
  • Functional impairment.

Prevention

  • Early identification and assessment of pain.
  • Proactive management based on WHO ladder.
  • Addressing psychosocial and spiritual factors.
  • Prophylactic management of predictable side effects (e.g., constipation).

Patient education

  • Pain is treatable; report pain accurately.
  • How the analgesic ladder works.
  • Importance of taking medication regularly ('by the clock') for constant pain.
  • How to use breakthrough medication.
  • Common side effects (esp. constipation with opioids) and how they are managed.
  • Importance of laxatives with regular opioids.
  • Non-drug pain relief methods.
  • Reassurance about addiction concerns with appropriate opioid use for pain.
  • Role of adjuvant medications.

Uganda-specific notes

Liquid morphine is available and effective. Trained palliative care professionals essential for chronic pain management. Holistic approach addressing psychosocial/spiritual factors is vital. NSAID use requires caution due to potential renal/GI issues.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 13, Sections 13.1, 13.1.1, 13.1.2, 13.1.2.3, 13.1.3, 13.1.4

For learning and professional reference. Use current local guidance and clinical judgement.

Browse all conditions
Scroll to Top